Intravenous Pegloticase Market Size

Intravenous Pegloticase Market size is poised to reach USD 13 Billion by the end of 2036, growing at a CAGR of 14% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of intravenous pegloticase was USD 3.5 Billion. The market is growing as a result of the rising prevalence of chronic and refractory gout among the global population. Intravenous pegloticase is used for the treatment of chronic and refractory gout in adults. It lowers uric acid levels and is typically prescribed when standard treatment has been ineffective. According to research, roughly 9.2 million people are afflicted with chronic and refractory gout, with men diagnosed more often than women.

In addition to these, the intravenous pegloticase market growth is owing to the aging global population. Gout typically occurs in men who are between the ages of forty and fifty years old. With people living longer lives than average, there is an increase in the number of geriatric people worldwide.